Tri Locum Partners LP Cel Sci Corp Transaction History
Tri Locum Partners LP
- $278 Million
- Q1 2024
Shares
1 transactions
Others Institutions Holding CVM
# of Institutions
83Shares Held
7.5MCall Options Held
61.8KPut Options Held
141K-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.39 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE879KShares$957,85612.54% of portfolio
-
Black Rock Inc. New York, NY763KShares$832,1520.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA669KShares$729,1980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$506,2050.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $47.3M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...